ES2733929T3 - Una combinación farmacéutica para el tratamiento del melanoma - Google Patents
Una combinación farmacéutica para el tratamiento del melanoma Download PDFInfo
- Publication number
- ES2733929T3 ES2733929T3 ES14822283T ES14822283T ES2733929T3 ES 2733929 T3 ES2733929 T3 ES 2733929T3 ES 14822283 T ES14822283 T ES 14822283T ES 14822283 T ES14822283 T ES 14822283T ES 2733929 T3 ES2733929 T3 ES 2733929T3
- Authority
- ES
- Spain
- Prior art keywords
- inhibitor
- melanoma
- compound
- braf
- antineoplastic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*c1c(C(C)=O)c(OC)cc(OC)c1[C@@]1CN(C)CC1 Chemical compound C*c1c(C(C)=O)c(OC)cc(OC)c1[C@@]1CN(C)CC1 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361845749P | 2013-07-12 | 2013-07-12 | |
| PCT/IB2014/063022 WO2015004636A1 (en) | 2013-07-12 | 2014-07-11 | A pharmaceutical combination for the treatment of melanoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2733929T3 true ES2733929T3 (es) | 2019-12-03 |
Family
ID=52279411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14822283T Active ES2733929T3 (es) | 2013-07-12 | 2014-07-11 | Una combinación farmacéutica para el tratamiento del melanoma |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US11007174B2 (enExample) |
| EP (1) | EP3019166B1 (enExample) |
| JP (5) | JP6568060B2 (enExample) |
| CN (3) | CN105530931B (enExample) |
| AR (1) | AR096892A1 (enExample) |
| AU (1) | AU2014288857B2 (enExample) |
| CA (1) | CA2917742C (enExample) |
| DK (1) | DK3019166T3 (enExample) |
| ES (1) | ES2733929T3 (enExample) |
| IL (1) | IL243572B (enExample) |
| TW (4) | TWI839690B (enExample) |
| WO (1) | WO2015004636A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI839690B (zh) | 2013-07-12 | 2024-04-21 | 印度商皮拉馬爾企業有限公司 | 治療黑色素瘤的藥物組合的用途 |
| JP7033451B2 (ja) * | 2015-06-05 | 2022-03-10 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシテイ オブ イリノイ | Ｐａｃ－１併用療法 |
| TWI804919B (zh) * | 2015-06-30 | 2023-06-11 | 美商建南德克公司 | 含藥物之立即釋放錠劑及形成該錠劑的方法 |
| AU2017232496B2 (en) * | 2016-03-16 | 2022-11-24 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the treatment of a beta-catenin-associated disease or disorder |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| WO2018213302A1 (en) * | 2017-05-16 | 2018-11-22 | Biomed Valley Discoveries, Inc. | Compositions and methods for treating cancer with atypical braf mutations |
| CA3082575A1 (en) | 2017-11-17 | 2019-05-23 | The Board Of Trustees Of The University Of Illinois | Cancer therapy by degrading dual mek signaling |
| CN107827726B (zh) * | 2017-11-28 | 2020-09-15 | 辽宁中医药大学 | 马齿苋中化合物Oleracone E及其提取分离方法 |
| CN108591464B (zh) * | 2018-06-28 | 2020-06-23 | 宁波奥克斯高科技有限公司 | 一种气体绝缘开关柜用密封结构 |
| CA3114385A1 (en) * | 2018-10-05 | 2020-04-09 | The Board Of Trustees Of The University Of Illinois | Combination therapy for the treatment of uveal melanoma |
| IL286993B2 (en) | 2019-04-11 | 2026-04-01 | Mei Pharma Inc | Polymorphs of vorocicliv and methods for their preparation and use |
| WO2021229439A1 (en) * | 2020-05-12 | 2021-11-18 | Novartis Ag | Therapeutic combinations comprising a craf inhibitor |
| CN112168821B (zh) * | 2020-11-09 | 2022-10-14 | 中南大学湘雅医院 | 一种治疗维罗非尼耐药的黑色素瘤的联合用药物及其应用 |
| AU2021381423A1 (en) * | 2020-11-19 | 2023-06-22 | Mei Pharma, Inc. | Treatment of kras mutant cancers |
| CN117043159A (zh) * | 2020-11-19 | 2023-11-10 | 梅制药公司 | Kras突变型癌症的治疗 |
| TW202430637A (zh) | 2022-11-16 | 2024-08-01 | 美商戴瑟納製藥股份有限公司 | Stat3靶向性寡核苷酸及其用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN164232B (enExample) | 1986-04-11 | 1989-02-04 | Hoechst India | |
| US5116954A (en) | 1988-04-06 | 1992-05-26 | Lipha, Lyonnaise Industrielle Pharmaceutique | Pharmaceutically useful flavonoic compounds containing at least one substituent on the benzopyranone ring moiety |
| USH1427H (en) | 1988-04-06 | 1995-04-04 | Briet; Phillipe | Substituted flavonoid compounds, their salts, their manufacture and their use in combination with interleukin-2 |
| US5284856A (en) | 1988-10-28 | 1994-02-08 | Hoechst Aktiengesellschaft | Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives |
| US5723313A (en) | 1995-09-27 | 1998-03-03 | St. Jude Children's Research Hospital | ARF-p19, a novel regulator of the mammalian cell cycle |
| US5733920A (en) | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
| US5849733A (en) | 1996-05-10 | 1998-12-15 | Bristol-Myers Squibb Co. | 2-thio or 2-oxo flavopiridol analogs |
| US6281223B1 (en) | 1999-04-13 | 2001-08-28 | Supergen, Inc. | Radioenhanced camptothecin derivative cancer treatments |
| GB2361236B (en) | 2000-03-29 | 2002-04-24 | Cyclacel Ltd | Pyrimidines useful against proliferative disorders |
| JP2003531899A (ja) | 2000-05-03 | 2003-10-28 | エルジー ライフ サイエンス リミテッド | ３−ヒドロキシクロメン−４−オン構造を有するｃｄｋ阻害剤 |
| CA2413702A1 (en) | 2000-06-28 | 2002-01-03 | Teva Pharmaceuticals Industries Ltd. | Carvedilol |
| US7915301B2 (en) | 2002-07-08 | 2011-03-29 | Piramal Life Science Limited | Inhibitors of cyclin dependent kinases and their use |
| US7271193B2 (en) * | 2002-07-08 | 2007-09-18 | Nicholas Piramal India, Ltd. | Inhibitors of cyclin-dependent kinases and their use |
| TWI331034B (en) | 2002-07-08 | 2010-10-01 | Piramal Life Sciences Ltd | Inhibitors of cyclin-dependent kinases and their use |
| US7884127B2 (en) | 2002-07-08 | 2011-02-08 | Pirimal Life Sciences Ltd. | Inhibitors of cyclin dependent kinases and their use |
| CA2502979A1 (en) | 2002-11-06 | 2004-05-21 | Cyclacel Limited | Pharmaceutical composition comprising a cdk inhibitor and gemcitabine |
| GB0328180D0 (en) | 2003-12-04 | 2004-01-07 | Cyclacel Ltd | Combination |
| ZA200604579B (en) | 2003-12-08 | 2007-10-31 | Univ Arizona | Synergistic anti-cancer compositions |
| CN101171241A (zh) | 2005-03-11 | 2008-04-30 | 密执安州立大学董事会 | 抗细胞凋亡的bcl-2家族成员的色烯-4-酮抑制剂及其应用 |
| MY153898A (en) * | 2005-06-22 | 2015-04-15 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| KR101209397B1 (ko) * | 2006-06-21 | 2012-12-06 | 피라말 라이프 사이언시스 리미티드 | 증식성 질환 치료용 광학이성적으로 순수한, 증식성 질환 치료용 플라본 유도체 및 이의 제조방법 |
| CA2658215C (en) | 2006-07-07 | 2013-08-27 | Piramal Life Sciences Limited | An enantioselective synthesis of pyrrolidines-substituted flavones |
| GB0706633D0 (en) | 2007-04-04 | 2007-05-16 | Cyclacel Ltd | Combination |
| CA2687204C (en) | 2007-05-15 | 2015-11-24 | Piramal Life Sciences Limited | A synergistic pharmaceutical combination for the treatment of cancer |
| US20100152129A1 (en) * | 2008-03-31 | 2010-06-17 | Periyasamy Giridharan | Novel synergistic combination of gemcitabine with P276-00 or P1446A in treatment of cancer |
| TWI461194B (zh) | 2009-05-05 | 2014-11-21 | Piramal Entpr Ltd | 吡咯啶取代黃酮作為輻射致敏劑 |
| MX2012009830A (es) | 2010-02-26 | 2013-02-11 | Piramal Entpr Ltd | Flavonas sustituidas de pirrolidina para el tratamiento de desordenes inflamatorios. |
| CN101841463B (zh) * | 2010-03-05 | 2012-05-16 | 清华大学 | 基于sctp的多路径并发传输方法 |
| JP5903433B2 (ja) * | 2010-08-26 | 2016-04-13 | ノバルティス アーゲー | 癌の治療に有用なｖｅｇｆｒ阻害剤およびｍｅｋ阻害剤の医薬的組み合わせ |
| CN104689318A (zh) | 2010-11-19 | 2015-06-10 | 葛兰素史密斯克莱知识产权（第2号）有限公司 | 使用braf抑制剂的治疗方法 |
| BR112013012313A2 (pt) | 2010-11-19 | 2019-09-24 | Piramal Enterprises Limited | combinação farmacêutica de paclitaxel e um inibidor de cdk |
| WO2012123889A1 (en) * | 2011-03-14 | 2012-09-20 | Piramal Healthcare Limited | A synergistic pharmaceutical combination for the treatment of pancreatic cancer |
| TW201300105A (zh) * | 2011-05-31 | 2013-01-01 | Piramal Life Sciences Ltd | 治療頭頸鱗狀細胞癌之相乘藥物組合物 |
| US20120321637A1 (en) * | 2011-06-20 | 2012-12-20 | The Board Of Regents Of The University Of Texas System | Combination cancer therapy with herv inhibition |
| AU2012274990A1 (en) | 2011-06-24 | 2014-02-06 | Piramal Enterprises Limited | Compounds for the treatment of cancers associated with human papillomavirus |
| TW201338774A (zh) | 2012-01-13 | 2013-10-01 | Piramal Entpr Ltd | 口腔粘膜炎預防或治療化合物 |
| WO2014049515A1 (en) | 2012-09-25 | 2014-04-03 | Piramal Enterprises Limited | Pyrrolidine substituted flavones for treatment of renal cystic diseases |
| WO2014128523A1 (en) | 2013-02-19 | 2014-08-28 | Piramal Enterprises Limited | A process for preparation of an intermediate of the pyrrolidine substituted flavones |
| TWI839690B (zh) | 2013-07-12 | 2024-04-21 | 印度商皮拉馬爾企業有限公司 | 治療黑色素瘤的藥物組合的用途 |
| EP3148532B1 (en) | 2014-05-28 | 2021-03-03 | Piramal Enterprises Limited | Pharmaceutical combination comprising a cdk inhibitor and a thioredoxin reductase inhibitor for the treatment of cancer |
-
2014
- 2014-07-11 TW TW111106633A patent/TWI839690B/zh active
- 2014-07-11 CN CN201480050507.6A patent/CN105530931B/zh active Active
- 2014-07-11 EP EP14822283.9A patent/EP3019166B1/en active Active
- 2014-07-11 JP JP2016524936A patent/JP6568060B2/ja active Active
- 2014-07-11 US US14/904,407 patent/US11007174B2/en active Active
- 2014-07-11 TW TW113110009A patent/TW202502325A/zh unknown
- 2014-07-11 AU AU2014288857A patent/AU2014288857B2/en active Active
- 2014-07-11 ES ES14822283T patent/ES2733929T3/es active Active
- 2014-07-11 CN CN202311581824.8A patent/CN117731786A/zh active Pending
- 2014-07-11 TW TW103123951A patent/TWI680760B/zh active
- 2014-07-11 AR ARP140102577A patent/AR096892A1/es not_active Application Discontinuation
- 2014-07-11 CA CA2917742A patent/CA2917742C/en active Active
- 2014-07-11 WO PCT/IB2014/063022 patent/WO2015004636A1/en not_active Ceased
- 2014-07-11 TW TW108142557A patent/TW202031253A/zh unknown
- 2014-07-11 DK DK14822283.9T patent/DK3019166T3/da active
- 2014-07-11 CN CN201911007262.XA patent/CN111053768B/zh active Active
-
2016
- 2016-01-11 IL IL24357216A patent/IL243572B/en active IP Right Grant
-
2018
- 2018-12-13 US US16/218,576 patent/US20190282544A1/en not_active Abandoned
-
2019
- 2019-08-01 JP JP2019141995A patent/JP2019206565A/ja active Pending
-
2020
- 2020-09-10 JP JP2020152028A patent/JP2021001186A/ja active Pending
-
2021
- 2021-02-05 US US17/168,876 patent/US11839591B2/en active Active
-
2022
- 2022-02-24 JP JP2022026851A patent/JP7799508B2/ja active Active
-
2023
- 2023-10-30 US US18/497,653 patent/US12383530B2/en active Active
- 2023-12-14 JP JP2023210858A patent/JP2024037891A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12383530B2 (en) | Pharmaceutical combination for the treatment of melanoma | |
| US20250332145A1 (en) | Pharmaceutical combination for the treatment of cancer | |
| ES2312568T3 (es) | Combinaciones antineoplasicas que comprenden cci-779 (derivado de rapamicina) junto con gemcitabina o fluoruracilo. | |
| Senkal et al. | Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo | |
| ES2791539T3 (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresión de DUX4 | |
| WO2023092943A1 (zh) | 盐酸决奈达隆联合5-氟尿嘧啶在制备抗肿瘤药物中的应用 | |
| CA2891300A1 (en) | Inhibition of drug resistant cancer cells | |
| Di Desidero et al. | Metronomic chemotherapy for triple negative breast cancer? | |
| TW202038960A (zh) | Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物 | |
| US20200061054A1 (en) | Use of dianhydrogalactitol or analogs and derivatives in combination with a p53 modulator or a parp inhibitor | |
| HK40026870A (en) | A pharmaceutical combination for the treatment of melanoma | |
| HK1224936A1 (en) | A pharmaceutical combination for the treatment of melanoma | |
| HK1224936B (en) | A pharmaceutical combination for the treatment of melanoma | |
| CA3198190A1 (en) | Use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] for treating cancers | |
| Di Desidero et al. | www. impactaging. com AGING, April 2016, Vol 8 No 4 |